InspireMD, Inc. (NSPR) Stock Forecast
NSPR analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.33 / 5 from 3 analysts
- Price target
- $3.33 average of analyst targets
- Upside to target
- +624.6% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.15
- 52-week range
- $0.46 – $2.35
NSPR analyst ratings
3 analystsNumber of analysts at each rating.
NSPR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NSPR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.16 | −$0.15 | −$0.17 | +9.8% | 3 |
| Current fiscal year (2026) | −$0.45 | −$0.63 | −$0.13 | −$0.76 | +40.4% | 3 |
| Next fiscal year (2027) | −$0.48 | −$0.52 | −$0.45 | −$0.45 | −6.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NSPR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.0M | $1.9M | $2.1M | −20.9% | 3 |
| Current fiscal year (2026) | $9.8M | $9.4M | $10.3M | +9.1% | 3 |
| Next fiscal year (2027) | $20.1M | $16.0M | $26.3M | +105.4% | 3 |
NSPR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NSPR revenue: reported and forecast
NSPR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.19 | −$0.19 | −$0.19 | −$0.15 | −17.9% | 3 up · 0 down |
| Current fiscal year (2026) | −$0.74 | −$0.74 | −$0.74 | −$0.74 | −$0.45 | −38.7% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.61 | −$0.61 | −$0.61 | −$0.61 | −$0.48 | −20.8% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NSPR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NSPR beat in 9 of 12.
What analysts expect from NSPR
3 analysts cover InspireMD; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.33, 624.6% above the latest close of $0.46. Analysts expect earnings of −$0.45 per share for 2026, +40.4% from a year earlier. For 2027 the average estimate is −$0.48 per share on revenue of $20.1 million. InspireMD beat the EPS estimate in 9 of the last 12 quarters.
Related: NSPR income statement, NSPR key metrics, NSPR chart. See the NSPR stock overview for the latest quote and news.
NSPR forecast FAQ
What is InspireMD's price target?
The average analyst price target for InspireMD is $3.33, 624.6% above the latest close of $0.46.
Is InspireMD a buy, hold or sell?
Of 3 analysts covering InspireMD, 1 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is InspireMD's EPS forecast?
Analysts forecast −$0.45 per share for 2026 (range −$0.63 to −$0.13); for 2027 the estimate is −$0.48.
What is InspireMD's revenue forecast?
The average revenue estimate for 2026 is $9.8 million, growth of 9.1%; for 2027 it is $20.1 million.
When does InspireMD report earnings?
InspireMD is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.15.
Does InspireMD usually beat earnings estimates?
InspireMD reported EPS at or above the analyst estimate in 9 of the last 12 quarters.